2018
Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
Inohara T, Xian Y, Liang L, Matsouaka R, Saver J, Smith E, Schwamm L, Reeves M, Hernandez A, Bhatt D, Peterson E, Fonarow G. Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA 2018, 319: 463-473. PMID: 29372247, PMCID: PMC5839299, DOI: 10.1001/jama.2017.21917.Peer-Reviewed Original ResearchConceptsHospital mortalityDual antiplatelet agentsIntracerebral hemorrhagePrior useOral anticoagulantsAntiplatelet agentsLower riskVitamin K Antagonist Oral AnticoagulantsK Antagonist Oral AnticoagulantsNon-vitamin K antagonistsGuidelines-Stroke hospitalsPrior antiplatelet therapyHospital mortality rateOral anticoagulant useRetrospective cohort studyWarfarin-treated patientsUse of OACInteraction p valuePrior strokeAnticoagulation therapyAntiplatelet therapyK antagonistsAnticoagulant useCohort studyHospital arrival
2017
Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes
Khan N, Siddiqui F, Goldstein J, Cox M, Xian Y, Matsouaka R, Heidenreich P, Peterson E, Bhatt D, Fonarow G, Schwamm L, Smith E. Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke 2017, 48: 1810-1817. PMID: 28596454, DOI: 10.1161/strokeaha.117.016290.Peer-Reviewed Original ResearchConceptsAntiplatelet therapyIntracerebral hemorrhageHospital mortalityPrevious useDiagnosis of ICHCombination antiplatelet therapyGuidelines-Stroke hospitalsPrestroke antiplatelet therapyTerms of comorbiditiesOral anticoagulant therapyIntracerebral hemorrhage outcomesAPT groupHigh-risk profileHospital presentationAnticoagulant therapyBaseline characteristicsAntiplatelet agentsHospital characteristicsHigh riskPatientsRisk profileMortalityTherapyAPT useComorbidities
2016
Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator
Xian Y, Federspiel J, Grau-Sepulveda M, Hernandez A, Schwamm L, Bhatt D, Smith E, Reeves M, Thomas L, Webb L, Bettger J, Laskowitz D, Fonarow G, Peterson E. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. JAMA Neurology 2016, 73: 1-10. PMID: 26551916, DOI: 10.1001/jamaneurol.2015.3106.Peer-Reviewed Original ResearchConceptsIntravenous tissue plasminogen activatorSymptomatic intracranial hemorrhageAcute ischemic strokePrestroke antiplatelet therapyTissue plasminogen activatorAntiplatelet therapyIschemic strokeGood functional outcomeHospital mortalityFunctional outcomeHigher oddsPlasminogen activatorDual antiplatelet treatmentGuidelines-Stroke registryRisk-adjusted likelihoodCardiovascular risk factorsRankin Scale scoreAmerican Heart AssociationAntiplatelet treatmentRegistry hospitalsRegistry patientsAmbulatory statusTPA administrationAdult patientsAntiplatelet agents
2010
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. Stroke 2010, 42: 227-276. PMID: 20966421, DOI: 10.1161/str.0b013e3181f7d043.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Sickle CellAnticoagulantsAtherosclerosisCerebral HemorrhageEmbolismEvidence-Based MedicineFemaleForamen Ovale, PatentHeart DiseasesHumansHyperhomocysteinemiaIschemic Attack, TransientMalePlatelet Aggregation InhibitorsPregnancyPregnancy Complications, CardiovascularRecurrenceRisk FactorsStrokeThrombophiliaThrombosisConceptsTransient ischemic attackEvidence-based recommendationsIschemic attackIschemic strokeCerebral venous sinus thrombosisTimely evidence-based recommendationsUse of anticoagulationVenous sinus thrombosisPrevention of strokeHigh-risk populationSickle cell diseaseImplementation of guidelinesAntithrombotic treatmentRecurrent strokeSinus thrombosisNoncardioembolic strokePostmenopausal hormonesAntiplatelet agentsArterial dissectionHypercoagulable statePatent foramenAtherosclerotic diseaseCerebral hemorrhageRisk factorsInterventional approaches
2006
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Sacco R, Adams R, Albers G, Alberts M, Benavente O, Furie K, Goldstein L, Gorelick P, Halperin J, Harbaugh R, Johnston S, Katzan I, Kelly-Hayes M, Kenton E, Marks M, Schwamm L, Tomsick T. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Circulation 2006, 113: e409-49. PMID: 16534023, DOI: 10.1161/circ.113.10.e409.Peer-Reviewed Original ResearchConceptsTransient ischemic attackEvidence-based recommendationsIschemic strokeIschemic attackCerebral venous sinus thrombosisTimely evidence-based recommendationsUse of anticoagulationVenous sinus thrombosisPrevention of strokeHigh-risk populationSickle cell diseaseImplementation of guidelinesAntithrombotic treatmentRecurrent strokeSinus thrombosisNoncardioembolic strokePostmenopausal hormonesAntiplatelet agentsArterial dissectionHypercoagulable statePatent foramenAtherosclerotic diseaseCerebral hemorrhageRisk factorsInterventional approachesGuidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Sacco R, Adams R, Albers G, Alberts M, Benavente O, Furie K, Goldstein L, Gorelick P, Halperin J, Harbaugh R, Johnston S, Katzan I, Kelly-Hayes M, Kenton E, Marks M, Schwamm L, Tomsick T. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke 2006, 37: 577-617. PMID: 16432246, DOI: 10.1161/01.str.0000199147.30016.74.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlcohol DrinkingAnti-Inflammatory Agents, Non-SteroidalBlood PressureBrain IschemiaClinical Trials as TopicComorbidityCoronary DiseaseDiabetes ComplicationsFemaleHumansHypertensionIschemic Attack, TransientMaleMiddle AgedObesityPrevalenceRiskRisk AssessmentRisk FactorsRisk Reduction BehaviorSmokingStrokeUnited StatesConceptsTransient ischemic attackEvidence-based recommendationsIschemic strokeIschemic attackCerebral venous sinus thrombosisTimely evidence-based recommendationsUse of anticoagulationVenous sinus thrombosisPrevention of strokeHigh-risk populationSickle cell diseaseImplementation of guidelinesAntithrombotic treatmentRecurrent strokeSinus thrombosisNoncardioembolic strokePostmenopausal hormonesAntiplatelet agentsArterial dissectionHypercoagulable statePatent foramenAtherosclerotic diseaseCerebral hemorrhageRisk factorsInterventional approaches